Metabolism and pharmacokinetics of MnDPDP in man

Acta Radiologica

Volumn 38, Issue 4 PART 2, 1997, Pages 677-689

  Toft, Kim Gunnar ^a   Hustvedt, S O ^a   Grant, D ^a   Martinsen, I ^a   Gordon, P B ^a   Friisk, G A ^a   Korsmo, A J ^a   Skotland, T ^a  

^a NYCOMED IMAGING AS   (Norway)

Author keywords

Contrast media; Dephosphorylation; Liver MR imaging; Metabolism; MnDPDP; Pharmacokinetics

Indexed keywords

CONTRAST MEDIUM; DRUG DERIVATIVE; EDETIC ACID; MANGANESE; N,N' BIS(PYRIDOXAL 5 PHOSPHATE)ETHYLENEDIAMINE N,N' DIACETIC ACID; N,N'-BIS(PYRIDOXAL-5-PHOSPHATE)ETHYLENEDIAMINE-N,N'-DIACETIC ACID; PYRIDOXAL 5 PHOSPHATE;

ARTICLE; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; FECES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLISM; METHODOLOGY; REFERENCE VALUE; STATISTICS; TIME;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EDETIC ACID; FECES; HUMANS; MALE; MANGANESE; PYRIDOXAL PHOSPHATE; REFERENCE VALUES; TIME FACTORS;

EID: 0031182136     PISSN: 02841851     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841859709172400     Document Type: Article

References (27)

1. 56 with tissue as demonstrated by blood clearance and liver uptake. J. Clin. Invest. 37 (1958), 1269.
2. DAVIDSSON L., CEDERBLAD A., LONNERDAL B. & SANDSTROM B.: Manganese retention in man. A method for estimating manganese absorption in man. Am. J. Clin. Nutr. 49 (1989), 170.
3. DINOTO D. R., KENNEDY C. D., JOHNSON J. A. et al.: Pharmacokinetics and biotransformation of the MRI liver contrast agent mangafodipir trisodium injection in normal human male volunteers. 4th Int. ISSX Meeting, Seattle 8 (1995), 323.
4. ELIZONDO G., FRETZ C. J., STARK D. D. et al.: Preclinical evaluation of MnDPDP. New paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 178 (1991), 73.
5. GIBBONS R. A., DIXON S. N., HALLIS K., RUSSELL A. M., SANSOM B. F. & SYMONDS H. W.: Manganese metabolism in cows and goats. Biochim. Biophys. Acta 444 (1976), 1.
6. GRANT D., ZECH K. & HOLTZ E.: Biodistribution and in vivo stability of manganese dipyridoxyl diphosphate in relation to imaging efficacy. Invest. Radiol. 29 (1994), S249.
7. HUSTVEDT S. O., GRANT D., SOUTHON T. E. & ZECH K.: Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration. Acta Radiol. 38 (1997), 690.
8. 2. Acta Radiol. 38 (1997), 740.
9. KANG Y. S. & GORE J. C.: Studies of tissue NMR relaxation enhancement by manganese. Dose and time dependences. Invest. Radiol. 19 (1984), 399.
10. LARSEN L. E. & GRANT D.: General toxicology of MnDPDP. Acta Radiol. 38 (1997), 770.
11. MAHONEY J. P. & SMALL W. J.: Studies on manganese. 3. The biological half-life of radiomanganese in man and factors which affect this half-life. J. Clin. Invest. 47 (1968), 643.
12. 2. Acta Radiol. 38 (1997), 700.
13. ROCKLAGE S. M., CACHERIS W. P., QUAY S. C., HAHN F. E. & RAYMOND K. N.: Manganese(II) N,N′-dipyridoxylethylene-diamine-N,N′-diacetate 5,5′-bis(phosphate). Synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg. Chem. 28 (1989), 477.
14. ROFSKY N. M., WEINREB J. C., BERNARDINO M. E., YOUNG S. W., LEE J. K. & NOZ M. E.: Hepatocellular tumors. Characterization with Mn-DPDP-enhanced MR imaging. Radiology 188 (1993), 53.
15. ROWLAND M. & TOZER T. N.: Clinical pharmacokinetics. Concepts and applications, 2nd edn. Lea & Febiger, Philadelphia 1989.
16. RUMMENY E. J., TORRES C. G., KURDZIEL J. C., NILSEN G., OP DE BEECK B. & LUNDBY B.: MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies. Acta Radiol. 38 (1997), 638.
17. SCHRAMM V. L. & BRANDT M.: The manganese(II) economy of rat hepatocytes. Fed. Proc. 45 (1986), 2817.
18. SCHROEDER H. A., BALASSA J. J. & TIPTON I. H.: Essential trace metals in man. Manganese. A study in homeostasis. J. Chronic Dis. 19 (1966), 545.
19. SHERWIN P. F., HUGO F. P., ROBISON R. O. et al.: Safety, tolerance, and pharmacokinetics of high doses of gadodiamide injection, a nonionic magnetic resonance contrast agent. Acad. Radiol. 1 (1994), S2.
20. SOUTHON T. E., GRANT D., BJØRNERUD A. et al.: NMR relaxation studies with MnDPDP. Acta Radiol. 38 (1997), 708.
21. 2+. Magn. Reson. Med. 8 (1988), 293.
22. TIRKKONEN B., AUKRUST A., COUTURE E. et al.: Physicochemical characterisation of mangafodipir trisodium. Acta Radiol. 38 (1997), 780.
23. TOFT K. G., FRIISK G. A. & SKOTLAND T.: Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging. Detection and quantitation of the parent compound MnDPDP and metabolites in human plasma by high performance liquid chromatography. J. Pharm. Biomed. Anal. 15 (1997), 973.
24. TOFT K. G., HUSTVEDT S. O., GRANT D., FRIISK G. A. & SKOTLAND T.: Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs. Eur. J. Drug Metab. Pharmacokinet. 22 (1997), 65.
25. TOFT K. G., KINDBERG G. M. & SKOTLAND T.: Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging. In vitro metabolism and protein binding studies of the active component MnDPDP in human blood. J. Pharm. Biomed. Anal. 15 (1997), 983.
26. TORRES C. G., LUNDBY B., TUFTE STERUD A., MCGILL S., GORDON P. B. & STRAND BJERKNES H.: MnDPDP for MR imaging of the liver. Results from the European phase III studies. Acta Radiol. 38 (1997), 631.
27. WANG C., GORDON P. B., HUSTVEDT S. O. et al.: MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers. Acta Radiol. 38 (1997), 665.